Скачать презентацию International Collaboration in FP 7 Health Research Dr Скачать презентацию International Collaboration in FP 7 Health Research Dr

8d6814a1dcbe4b03f746afabb0c02b3e.ppt

  • Количество слайдов: 29

International Collaboration in FP 7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects International Collaboration in FP 7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects and Coordination Indridi. [email protected] europa. eu

Outcome of FP 6 Reminder: ALL RESEARCH TOPICS WERE OPEN FOR 3 rd COUNTRY Outcome of FP 6 Reminder: ALL RESEARCH TOPICS WERE OPEN FOR 3 rd COUNTRY PARTICIPANTS • At least 3 organizations from EU and/or associated states • In addition, “third country” participants were welcome • Partners from the INCO target countries, could receive funding Indridi. [email protected] europa. eu

Indridi. Benediktsson@ec. europa. eu Indridi. [email protected] europa. eu

Outcome of FP 6 • € 2. 4 billion for health research; 604 projects Outcome of FP 6 • € 2. 4 billion for health research; 604 projects over the 4 years • Average success rate: 25. 4% • Total number of participants: 7, 426 Project type number av. EC contribution Integrated Projects 119 € 10. 0 m 21 40 € 9. 3 m 30 322 € 2. 2 m 8 Coordination Actions 25 € 1. 1 m 19 Specific Support Actions 98 € 0. 4 m 6 Networks of Excellence STRe. Ps Indridi. [email protected] europa. eu partners

3 rd countries’ participation in FP 6 Health Research Number of 3 rd country 3 rd countries’ participation in FP 6 Health Research Number of 3 rd country participants in Health projects Number of participants (Top Ten) In total: 245 participants from 51 third countries Indridi. [email protected] europa. eu

Timeframe for FP 7 projects Results from FP 7 projects in use Projects resulting Timeframe for FP 7 projects Results from FP 7 projects in use Projects resulting from FP 7 calls operating Official duration of FP 7 2007 -2013 2006 First calls 2007 2008 2009 2010 First projects start Indridi. [email protected] europa. eu 2011 2012 2013 2014 Last projects start 2015 2016 2017 2018 2019 2020 Last projects end 2021

Cooperation – Collaborative Research Nine themes 1. 2. 3. 4. 5. 6. 7. 8. Cooperation – Collaborative Research Nine themes 1. 2. 3. 4. 5. 6. 7. 8. 9. + Health Food, agriculture, fisheries and biotechnology Information and communication technologies Nanosciences, nanotechnologies, materials and new production technologies Energy Environment (including climate change) Transport (including aeronautics) Socio-economic sciences and the humanities Security and space Euratom: Fusion energy research, nuclear fission and radiation protection Indridi. [email protected] europa. eu

Collaborative Research changing priorities (relative weight) Security + Space Socio -economic Transport Environment Industrial Collaborative Research changing priorities (relative weight) Security + Space Socio -economic Transport Environment Industrial + materials tech. ICT Energy Life Sciences* FP 1 Indridi. [email protected] europa. eu FP 2 FP 3 FP 4 FP 5 FP 6 FP 7 *from FP 6 split into: Health + Food/Agri/Biotech

Health Research Objectives: – Improving the health of European citizens – Increasing the competitiveness Health Research Objectives: – Improving the health of European citizens – Increasing the competitiveness of European health-related industries and business – Addressing global health issues including emerging epidemics Indridi. [email protected] europa. eu

Health Research Rationale for pan-European approach (I): Ø Sequencing of human genome advances in Health Research Rationale for pan-European approach (I): Ø Sequencing of human genome advances in post-genomics + vast amount of data, accelerated discovery Ø Translational research multidisciplinary Ø Health policy-driven research comparisons of national models & data Indridi. [email protected] europa. eu

Health Research Rationale for pan-European approach (II): – Strong EU-based biomedical research strengthen the Health Research Rationale for pan-European approach (II): – Strong EU-based biomedical research strengthen the competitiveness of large industries (pharma) and SMEs (healthcare biotech & medical technology) • Transnational co-operation is essential to face the worldwide competition • Contribute to the development of norms & standards to set up appropriate legislative framework for new medical technologies (e. g. regenerative medicine) Indridi. [email protected] europa. eu

1. Health • Budget: Ø € 6 billion over 7 years (2007 -2013) Three 1. Health • Budget: Ø € 6 billion over 7 years (2007 -2013) Three pillars of activities: • Biotechnology, generic tools and technologies for human health • Translating research for human health • Optimising the delivery of healthcare to European citizens Indridi. [email protected] europa. eu

Collaborative research in Health 1: Biotechnology, generic tools and technologies Ø High-throughput research (enhancing Collaborative research in Health 1: Biotechnology, generic tools and technologies Ø High-throughput research (enhancing data generation, standardisation, acquisition & analysis) Ø Detection, diagnosis and monitoring (with emphasis on non-invasive or minimally invasive approaches) Ø Innovative therapeutic approaches and interventions (with potential application in many diseases and disorders) Ø Predicting suitability, safety and efficacy of therapies (biological markers, in vivo and in vitro methods and models, simulation, pharmacogenomics, targeting etc. ) Indridi. [email protected] europa. eu

Collaborative research in Health 2: Translating research for human health Ø Integrating biological data Collaborative research in Health 2: Translating research for human health Ø Integrating biological data and processes: (large-scale data gathering, systems biology) Ø Research on the brain and neurological diseases, human development and ageing Ø Infectious diseases: to confront major threats to public health (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics, NID) Ø Other major diseases: (cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases) Indridi. [email protected] europa. eu

Collaborative research in Health 3: Optimising the delivery of health care Ø Enhanced health Collaborative research in Health 3: Optimising the delivery of health care Ø Enhanced health promotion and disease prevention (providing evidence of best public health measures – life styles, interventions, special focus on mental health etc. ) Ø Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking etc. ) Ø Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems etc. ) Indridi. [email protected] europa. eu

European Technology Platform The Innovative Medicines Initiative Indridi. Benediktsson@ec. europa. eu European Technology Platform The Innovative Medicines Initiative Indridi. [email protected] europa. eu

15 Medicine 10 5 years Indridi. Benediktsson@ec. europa. eu Idea Creating new medicines is 15 Medicine 10 5 years Indridi. [email protected] europa. eu Idea Creating new medicines is a high risk journey

The Innovative Medicines Initiative Starting point: – drug development: increasing cost, duration and risk The Innovative Medicines Initiative Starting point: – drug development: increasing cost, duration and risk – competitiveness of pharmaceutical industry affected – EU concerned by loss of leadership in pharma R&D Response: the Innovative Medicines Initiative – collaborative effort between EC and pharmaceutical industry (EFPIA) – tackle specific issues where research is the key – Public Private Partnership for implementation Indridi. [email protected] europa. eu

Calls for proposals in 2007 Health theme • First calls for proposals issued 22 Calls for proposals in 2007 Health theme • First calls for proposals issued 22 Dec. ’ 06 Ø first deadline: 19 April 2007 € 628 million Ø second deadline: 18 September 2007 € 532 million 1 [ not all areas will be open in each call ] 1: pending approval of 2008 budget Indridi. [email protected] europa. eu

Evaluation Peer review by invited experts Criteria: • S+T quality -of the concept, objectives Evaluation Peer review by invited experts Criteria: • S+T quality -of the concept, objectives and methodology • Impact -potential impact, dissemination, exploitation, use • Implementation -management, quality of consortium, resources Indridi. [email protected] europa. eu

International Collaboration -issues at stake: A) Development assistance policy objectives, e. g. Millennium Development International Collaboration -issues at stake: A) Development assistance policy objectives, e. g. Millennium Development Goals targets: poor countries, e. g. ACP B) Strengthening EU competitiveness competing with industrialised countries (e. g. attracting excellence) collaboration for mutual gains targets: more developed countries (e. g. BRIC) C) Science diplomacy collaborating w. industrialised countries “ice breaking” when collaborating w. new partner countries putting “meat on the bones” of S+T agreements a sign of maturity of the FPs (openness) targets: OECD, all 3 rd countries Indridi. [email protected] europa. eu

International Collaboration -what is new in FP 7? The management of thematic INCO projects International Collaboration -what is new in FP 7? The management of thematic INCO projects moves from the INCO directorate to thematic directorates INCO-Health to Health Research -better synergies with traditional collaborative projects in theme -greater visibility for INCO projects as part of a larger portfolio Indridi. [email protected] europa. eu

International Collaboration in FP 7 2 different avenues: 1. All activities open for International International Collaboration in FP 7 2 different avenues: 1. All activities open for International Cooperation Partner Countries (ICPCs) can participate in projects and receive EC funding § Minimum number of participants: 3 from MS/AS § § 2. Specific International Cooperation Actions § Address specific issues of partner countries or with a global character, on the basis of mutual interest and benefit § Minimum number of participants: 2+2 (2 from MS/AS + 2 from ICPCs) Indridi. [email protected] europa. eu

International Collaboration in FP 7 Health Example of a SICA topics in the first International Collaboration in FP 7 Health Example of a SICA topics in the first Work Programme (deadlines in 2007) Childhood and adolescent mental disorders The research should be aimed at investigating paediatric mental disorders that have a high prevalence in countries of Central and Eastern Europe. The projects should use population genetics/genomics approaches and include bioinformatics/biostatistics to increase knowledge of the patterns of disease prevalence and develop possible diagnostic and therapeutic strategies as well as address prevention. Indridi. [email protected] europa. eu

International Collaboration in FP 7 Health Example of a SICA topics in the first International Collaboration in FP 7 Health Example of a SICA topics in the first Work Programme (deadlines in 2007) Epidemiological investigations into long-term trends of population health as consequence of socioeconomic transitions, including life-style induced health problems Investigations into tackling the burden of chronic diseases such as diabetes, cardiovascular and liver diseases, for identifying strategies at the population level to implement effective solutions to improve health. Specific International Cooperation Action. Targeted regions: Mediterranean Partner countries, Russia, Eastern European and Central Asia. Indridi. [email protected] europa. eu

International Collaboration in FP 7 Health Other initiatives International activities in large scale data International Collaboration in FP 7 Health Other initiatives International activities in large scale data gathering for functional genomics -organising and coordinating endeavours aiming at collecting, integrating and curating genomics, proteomics, population genetics, comparative and functional genomics data and/or samples of relevance to human health Indridi. [email protected] europa. eu

Collaborative Health research in FP 7 SUMMARY Continuity in collaborative Health research to: Ø Collaborative Health research in FP 7 SUMMARY Continuity in collaborative Health research to: Ø develop new tools and technologies Ø promote translational research Ø optimise delivery of health care [ using usual FP funding mechanisms ] & A novel approach to improve drug development: Ø The Innovative Medicines Initiative [ using the proposed Joint Technology Initiative in FP 7 ] Indridi. [email protected] europa. eu

Indridi. Benediktsson@ec. europa. eu Indridi. [email protected] europa. eu

Information • EU research: http: //ec. europa. eu/research • Seventh Framework Programme: http: //ec. Information • EU research: http: //ec. europa. eu/research • Seventh Framework Programme: http: //ec. europa. eu/research/fp 7 • Information on research programmes and projects: http: //www. cordis. lu/ • RTD info magazine: http: //ec. europa. eu/research/rtdinfo/ • Information requests: http: //ec. europa. eu/research/enquiries/ Indridi. [email protected] europa. eu